EFX

Contact Hagens Berman by June 25, 2024 Deadline to Join Class Action Against Akero Therapeutics (AKRO)

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Cirrhosis, EFX, Liver disease, News, Risk, Fatty liver disease, NASH, Patient, Failure, Hagens Berman, Clinical trial, Therapy, SAN, Person, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now .

Key Points: 
  • SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now .
  • Akero Therapeutics, Inc. (AKRO) Securities Fraud Class Action:
    Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is facing a securities class action lawsuit over allegations it misled investors about a key clinical trial.
  • The lawsuit centers on the SYMMETRY study, designed to evaluate efruxifermin ("EFX"), Akero's lead drug candidate, for treating nonalcoholic steatohepatitis (NASH), a serious liver condition.
  • "We are investigating whether Akero intentionally misrepresented its SYMMETRY patient population," stated Reed Kathrein, the Hagens Berman partner leading the investigation.

DEADLINE ALERT for ADSK, CMP, AKRO, EXAI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Mercoledì, Maggio 8, 2024
FDA, Cirrhosis, Compass Minerals, Inflammation, NAFLD, Investment, EFX, Risk, Suite, Class, Steatosis, NASH, Law, Ethics, Patient, Defendant, Åkerö, Telephone, Knowledge

BENSALEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, Akero, and Equinix and Encourages Investors to Contact the Firm

Retrieved on: 
Mercoledì, Maggio 8, 2024
Cirrhosis, EQIX, EFX, Liver disease, News, Risk, Pharma, Complaint, Fatty liver disease, Artificial intelligence, Employment, P.C, NASH, Ethics, Patient, Principal, Defendant, Knowledge, Food and Drug Administration, Audit

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Exscientia in an artificial intelligence ("AI") driven Pharma-tech company that engages in the design and develop differentiated medicines for diseases with high unmet patient needs.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Equinix class action go to: https://bespc.com/cases/EQIX

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Retrieved on: 
Mercoledì, Maggio 8, 2024
Cirrhosis, LLP, EFX, Liver disease, News, Advertising, Fatty liver disease, NASH, Patient, Court, Fibrosis, Food and Drug Administration, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Akero’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Mercoledì, Maggio 8, 2024
Sale, FDA, Cirrhosis, Inflammation, EFX, Liver disease, News, Complaint, Fatty liver disease, Research, Steatosis, NASH, Patient, Court, DSM-IV codes, Drug development, Person, Disclosure

The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.

Key Points: 
  • The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.
  • To finance the Company’s operations, Akero conducted two secondary stock offerings and one at-the-market stock offering during the Class Period, raising over $577 million.
  • If you suffered a loss in Akero you have until June 25, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.

Retrieved on: 
Martedì, Maggio 7, 2024
FDA, Efficacy, Cirrhosis, Inflammation, LLP, NAFLD, EFX, Liver disease, Viability, Fatty liver disease, Steatosis, NASH, Complaint, Patient, DSM-IV codes, SAN, Person, Pharmaceutical industry

Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.

Key Points: 
  • Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.
  • The Company is currently focused on advancing its lead product candidate efruxifermin (“EFX”) to provide a new treatment for patients with nonalcoholic steatohepatitis ("NASH"), a serious liver disease.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Akero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit – Hagens Berman

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, Cirrhosis, EFX, Liver disease, News, Risk, Fatty liver disease, NASH, Patient, Failure, Hagens Berman, Clinical trial, Therapy, SAN, Person

SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now .

Key Points: 
  • SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now .
  • Akero Therapeutics, Inc. (AKRO) Securities Fraud Class Action:
    Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is facing a securities class action lawsuit over allegations it misled investors about a key clinical trial.
  • The lawsuit centers on the SYMMETRY study, designed to evaluate efruxifermin ("EFX"), Akero's lead drug candidate, for treating nonalcoholic steatohepatitis (NASH), a serious liver condition.
  • "We are investigating whether Akero intentionally misrepresented its SYMMETRY patient population," stated Reed Kathrein, the Hagens Berman partner leading the investigation.

Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc.

Retrieved on: 
Domenica, Maggio 5, 2024
Sale, FDA, Lead, Cirrhosis, Fatty liver disease, LLP, EFX, News, NASH, 8-K, District court, HERE, Patient, Non-alcoholic fatty liver disease, Histology, Fibrosis, Drug development, Therapy, Pharmaceutical industry

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Akero’s materially misleading statements and omissions to the public, Akero’s investors have suffered significant losses.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

Retrieved on: 
Giovedì, Maggio 9, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Cirrhosis, Inflammation, NAFLD, EFX, News, Suite, Steatosis, NASH, Law, Patient, Defendant, Court, Åkerö, Telephone, Cryptocurrency

Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
  • On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors

Retrieved on: 
Martedì, Maggio 7, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Cirrhosis, Inflammation, NAFLD, EFX, News, Suite, GPM, Steatosis, NASH, Patient, Defendant, Court

Akero investors have until June 25, 2024 to file a lead plaintiff motion.

Key Points: 
  • Akero investors have until June 25, 2024 to file a lead plaintiff motion.
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
  • On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.